Melanotan II
Melanotan II
Regulatory Status
Often cited in safety discussions because of adverse-effect and misuse concerns.
FDA · Updated Apr 2026
Frequently treated as a research-only compound.
MHRA · Updated Apr 2026
Commercial use and import treatment remains sensitive.
TGA · Updated Apr 2026
Not specifically addressed in the current WADA notes used here.
WADA · Updated Apr 2026
Overview
Melanotan II is one of the most controversial peptides in the commercial market because demand is often driven by tanning claims rather than a robust clinical evidence base. It frequently appears in safety-centered regulatory discussions.
Continue Reading
Readers also explore
State of Peptides 2026
Get the free report and peptide profile updates.
Evidence notes, regulatory changes, and practical research guides in your inbox. Education only - not medical advice.
Get the PeptideUnicorn update
New profiles, regulatory changes, practical guides, and vendor review notes delivered to your inbox.
Get our free State of Peptides 2026 report when you subscribe.